242 related articles for article (PubMed ID: 22234678)
21. Allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A single center experience.
Schmohl JU; Groh C; Faul C; Vogel W; Möhle R; Wirths S; Schneidawind D; Kanz L; Bethge WA
Ann Hematol; 2016 May; 95(6):973-83. PubMed ID: 27021303
[TBL] [Abstract][Full Text] [Related]
22. Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.
Alchalby H; Yunus DR; Zabelina T; Kobbe G; Holler E; Bornhäuser M; Schwerdtfeger R; Bethge W; Kvasnicka HM; Büsche G; Ayuk F; Bacher U; Zander AR; Kröger N
Br J Haematol; 2012 Apr; 157(1):75-85. PubMed ID: 22280409
[TBL] [Abstract][Full Text] [Related]
23. Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients.
Tefferi A; Jimma T; Gangat N; Vaidya R; Begna KH; Hanson CA; Van Dyke DL; Caramazza D; Pardanani A
Blood; 2011 Oct; 118(17):4595-8. PubMed ID: 21881047
[TBL] [Abstract][Full Text] [Related]
24. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation.
Gagelmann N; Ditschkowski M; Bogdanov R; Bredin S; Robin M; Cassinat B; Shahswar R; Thol F; Heuser M; Socié G; Beelen D; Triviai I; Badbaran A; Kröger N
Blood; 2019 May; 133(20):2233-2242. PubMed ID: 30760453
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic stem cell transplantation for myelofibrosis patients aged ≥65 years.
Daghia G; Zabelina T; Zeck G; von Pein UM; Christopeit M; Wolschke C; Ayuk F; Kröger N
Eur J Haematol; 2019 Oct; 103(4):370-378. PubMed ID: 31306511
[TBL] [Abstract][Full Text] [Related]
27. Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?
Lestang E; Peterlin P; Le Bris Y; Dubruille V; Delaunay J; Godon C; Theisen O; Blin N; Mahe B; Gastinne T; Garnier A; Touzeau C; Voldoire M; Bene MC; Le Gouill S; Milpied N; Mohty M; Moreau P; Guillaume T; Chevallier P
Eur J Haematol; 2017 Jul; 99(1):60-69. PubMed ID: 28370306
[TBL] [Abstract][Full Text] [Related]
28. [A study of prognostic value of cytogenetics in patients with primary myelofibrosis].
Li B; Xu J; Xu Z; Li C; Qin T; Fang L; Zhang H; Hu N; Pan L; Qu S; Wang J; Zhang Y; Zhang P; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):990-4. PubMed ID: 25417875
[TBL] [Abstract][Full Text] [Related]
29. Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.
Elena C; Passamonti F; Rumi E; Malcovati L; Arcaini L; Boveri E; Merli M; Pietra D; Pascutto C; Lazzarino M
Haematologica; 2011 Jan; 96(1):167-70. PubMed ID: 20884708
[TBL] [Abstract][Full Text] [Related]
30. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.
Goldman JM; Majhail NS; Klein JP; Wang Z; Sobocinski KA; Arora M; Horowitz MM; Rizzo JD
J Clin Oncol; 2010 Apr; 28(11):1888-95. PubMed ID: 20212247
[TBL] [Abstract][Full Text] [Related]
31. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
32. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2014 Sep; 89(9):915-25. PubMed ID: 25124313
[TBL] [Abstract][Full Text] [Related]
33. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis.
Kröger N; Giorgino T; Scott BL; Ditschkowski M; Alchalby H; Cervantes F; Vannucchi A; Cazzola M; Morra E; Zabelina T; Maffioli M; Pereira A; Beelen D; Deeg HJ; Passamonti F
Blood; 2015 May; 125(21):3347-50; quiz 3364. PubMed ID: 25784679
[TBL] [Abstract][Full Text] [Related]
34. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.
Raj K; Eikema DJ; McLornan DP; Olavarria E; Blok HJ; Bregante S; Ciceri F; Passweg J; Ljungman P; Schaap N; Carlson K; Zuckerman T; de Wreede LC; Volin L; Koc Y; Diez-Martin JL; Brossart P; Wolf D; Blaise D; Bartolomeo PD; Vitek A; Robin M; Yakoub-Agha I; Chalandon Y; Kroger N
Biol Blood Marrow Transplant; 2019 Mar; 25(3):522-528. PubMed ID: 30408564
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of splenomegaly on survival of Chinese with primary myelofibrosis.
Wang J; Xu J; Gale RP; Xu Z; Li B; Qin T; Zhang Y; Fang L; Zhang H; Pan L; Qu S; Zhang P; Xiao Z
Leuk Res; 2014 Oct; 38(10):1207-11. PubMed ID: 25182689
[TBL] [Abstract][Full Text] [Related]
36. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution.
Tefferi A; Huang J; Schwager S; Li CY; Wu W; Pardanani A; Mesa RA
Cancer; 2007 May; 109(10):2083-8. PubMed ID: 17407134
[TBL] [Abstract][Full Text] [Related]
37. Prognostication in primary myelofibrosis.
Cervantes F; Pereira A
Curr Hematol Malig Rep; 2012 Mar; 7(1):43-9. PubMed ID: 22072485
[TBL] [Abstract][Full Text] [Related]
38. Comparison of Outcomes of Allogeneic Transplantation for Primary Myelofibrosis among Hematopoietic Stem Cell Source Groups.
Murata M; Takenaka K; Uchida N; Ozawa Y; Ohashi K; Kim SW; Ikegame K; Kanda Y; Kobayashi H; Ishikawa J; Ago H; Hirokawa M; Fukuda T; Atsuta Y; Kondo T
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1536-1543. PubMed ID: 30826464
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.
Palandri F; Breccia M; Tiribelli M; Bonifacio M; Benevolo G; Iurlo A; Elli EM; Binotto G; Tieghi A; Polverelli N; Martino B; Abruzzese E; Bergamaschi M; Heidel FH; Cavazzini F; Crugnola M; Bosi C; Isidori A; Auteri G; Forte D; Latagliata R; Griguolo D; Cattaneo D; Trawinska M; Bartoletti D; Krampera M; Semenzato G; Lemoli RM; Cuneo A; Di Raimondo F; Vianelli N; Cavo M; Palumbo GA
Hematol Oncol; 2020 Aug; 38(3):372-380. PubMed ID: 32271957
[TBL] [Abstract][Full Text] [Related]
40. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.
Tamari R; Rapaport F; Zhang N; McNamara C; Kuykendall A; Sallman DA; Komrokji R; Arruda A; Najfeld V; Sandy L; Medina J; Litvin R; Famulare CA; Patel MA; Maloy M; Castro-Malaspina H; Giralt SA; Weinberg RS; Mascarenhas JO; Mesa R; Rondelli D; Dueck AC; Levine RL; Gupta V; Hoffman R; Rampal RK
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1142-1151. PubMed ID: 30625392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]